Teclistamab  (Synonyms: 特立妥单抗)

Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM)^[1].

Human IgG4 lambda

Human IgG4 (S228P) lambda1, Isotype Control

Bispecific; Human ; Chimeric

Teclistamab (0.01-1000 nM, 48 h) 可以诱导 T 细胞介导的细胞毒性，在 H929 细胞中的 EC₅₀ 值为 0.15 nM，在MM.1R 细胞系中为 0.06 nM，在 RPMI 8226 细胞系中为 0.45 nM^[1]。
Teclistamab (0.01-1000 nM, 48 h) 能以剂量依赖方式结合 CD138 ⁺人 BM 单核细胞，并诱导人 BM 单核细胞的细胞毒性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG（NOD/SCID/γc^-/）小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2119595-80-9

液体

Colorless to light yellow

特立妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 lambda

• 
  Immobilized Human CD3 epsilon/CD3e Protein (ECD, His Tag) can bind Teclistamab. The EC₅₀ for this effect is 1.56 ng/mL.
• 
  Immobilized Human BCMA Protein (ECD, His Tag) can bind Teclistamab. The EC₅₀ for this effect is 0.18 ng/mL.

• [1]. Kodandaram Pillarisetti, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020 Sep 22;4(18):4538-4549.  [Content Brief]